Evvy, known for its pioneering work in vaginal microbiome testing, today announced its expansion into treatments with a new line of prescription-grade products for vaginal symptom relief. The launch marks a significant milestone for the female-founded startup, as it’s the first time patients can access Evvy’s prescription products without first taking their vaginal microbiome test.
The new product line includes prescription-grade suppositories and creams designed to address common vaginal health concerns such as pH imbalance, dryness, odor, and irritation. All products are compounded in a 503a NABP-accredited pharmacy and formulated without PFAs, parabens, BPAs, phthalates, sulfites, artificial dyes, and fragrances.
“Vaginal discomfort remains a leading reason women and people with vaginas seek medical advice, yet patients lack access to high-quality, effective solutions,” says Dr. Kate McLean, Evvy’s Chief Medical Officer. “Our Vaginal Health Test has already helped tens of thousands of patients pinpoint and treat the root cause of their vaginal symptoms. With this launch, we’re expanding access to our science-backed symptom relief treatments to provide a comprehensive approach that delivers both immediate relief and long-term results.”
The treatments, which include boric acid and hyaluronic acid suppositories as well as specialized vulva creams, are available through Evvy’s website. Patients are matched with an Evvy-affiliated provider who reviews their health information and can prescribe the products.
While these new treatments focus on immediate symptom relief, Evvy continues to emphasize the importance of their Vaginal Health Test in identifying root causes. The test is CLIA/CAP/CLEP-certified, and capable of testing for over 700 bacteria and fungi with a single swab.
“Our new prescription product line will empower patients to manage their symptoms quickly and confidently while Evvy’s advanced testing gets to the root cause of their symptoms,” explains Priyanka Jain, co-founder and CEO of Evvy. “Once patients receive results from our world-leading vaginal microbiome test, we can go beyond symptom relief to deliver personalized care that supports long-term microbiome health for each patient.”
The launch reflects Evvy’s broader mission to revolutionize vaginal health with science-backed, personalized care, particularly important at a time when access to women’s healthcare is increasingly challenged nationwide. The company’s new treatments are currently available in 39 states, with plans to expand in 2025, while their Vaginal Health Test continues to be available across all 50 states.
